⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 17, 2024

Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Sun Min Lim Seong-san Kang Dong Kwon Kim Soo‐Hwan Lee Chun‐Bong Synn Sujeong Baek Seung M. Yang Yu J. Han Mi H. Kim Heekyung Han Kwangmin Na Young T. Kim Mi Ran Yun Jae Hwan Kim Youngseon Byeon Young Seo Kim Jii Bum Lee Min Hee Hong Joshua C. Curtin Bharvin Patel Isabelle Bergiers Kyoung‐Ho Pyo Byoung Chul Cho

View at Publisher

Ask AI

Bookmark

Share

Abstract

Data legend for supplementary data 1, showing the process chart and raw whole slide images of multiplex IHC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e60020b6db6435875941ed https://doi.org/10.1158/2767-9764.26318634

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
2Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
3Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
4Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
5Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024

Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
Supplementary Figure 2 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024